MOBI · Mobia Medical, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on MOBI. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About MOBI · Mobia Medical, Inc.
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
MOBI completed its IPO on May 11, 2026 at $15/share and began trading on Nasdaq Global Select Market. The stock immediately sold off ~20% to the ~$12 area as of current data (May 8-11 2026). The company is a commercial-stage medical device firm with one FDA-approved product — the Vivistim Paired VNS System for chronic ischemic stroke recovery — generating $32M in 2025 revenue (+105% YoY) but deeply unprofitable (-$46.5M net loss, -$29.4M FCF deficit). The insider cluster is real and concentrated: several directors and officers made open-market purchases at the $15 IPO price on May 11, 2026 (total ~$8-9M across multiple insiders), but this coincided with a company that had just gone public days earlier. These appear to be post-IPO participation buys rather than informed insider signals about intrinsic value divergence. No options chain exists yet (recently listed). The fundamental picture is mixed: strong 81% gross margins and rapid revenue growth are offset by no clear profitability path, ~$158M cumulative deficit, limited payor coverage for the device, and a thin public float (~3M shares out of 33M total). This is fundamentally a pre-profitability story in its first week as a public company — insufficient data on which to build any structured income or directional thesis.